Logistics

The pharmaceutical industry is entering a period of intensified trade disruption. With new tariffs on imported raw materials, active pharmaceutical ingredients (APIs), and medical components, global supply chains that once prioritized efficiency are now facing rising costs, increased complexity, and growing regulatory risk. For companies developing biologics and Antibody-drug conjugates (ADCs), the impact is particularly acute. read more

The pharmaceutical supply chain faces unprecedented complexity in 2025, balancing accelerating scientific innovation with mounting operational and regulatory pressures. Below, we analyze critical challenges, regulatory shifts, and emerging technologies reshaping this $1.5 trillion global industry. read more

Kincell Bio and Cellipont Bioservices have completed their merger to form Kincellis Advanced Therapies, a U.S.-based contract development and manufacturing organization focused on cell therapies and other advanced modalities. read more

mAbxience and Sandoz have signed a licensing, development, manufacturing and commercialization agreement for a proposed biosimilar version of emicizumab, a treatment used for hemophilia A. read more